| N=178 |
|
Sd |
SE |
Min |
Max |
Cv |
CI |
| OC1 |
31.79 |
12.76 |
.96 |
4.1 |
78.9 |
40.15 |
29.90-33.67 |
| CL1 |
551.23 |
268.11 |
20.09 |
18.8 |
1290.0 |
48.64 |
511.57-590.90 |
| OC2 |
20.96 |
9.86 |
.74 |
3.0 |
63.6 |
47.06 |
19.50-22.42 |
| CL2 |
200.89 |
144.31 |
10.82 |
10.0 |
712.6 |
71.83 |
179.54-222.24 |
Assymetry and flattening values ranging from -.04 to .04 were not discussed.
Minimal (min) i maximal (max) values of bone markers of participants compared
to the sample of 178 participants indicate that the values are within the expected
range. Larger values of coefficient of variation denote that there is heterogeneity
compared to the sample of 178 participants in terms of: OC1 (40.15), CL1 (48.64),
OC2 (47.06), CL2 (71.83). There is significant statistical difference between
starting values and therapeutic ones for both biochemical bone markers (p<0.000).
Also, the percentage of osteocalcin change is 34.07%, and the percentage of
βCTx change is 63,56% which exceeds values of least significant change (LSC),
necessary to conclude that the difference is the effect of receiving bisphosphonate
therapy |
